Purdue Pharma's Sentencing Delayed Amidst Opioid Crisis
A federal judge paused the sentencing of Purdue Pharma for a week to enable more public involvement in its opioid case. Meanwhile, Johnson & Johnson plans to sell four medications on the TrumpRx website. These events highlight ongoing legal and pharmaceutical industry dynamics amid the opioid epidemic.
A federal judge has decided to postpone the criminal sentencing of Purdue Pharma, a move that underscores the complexity and sensitivity of the ongoing opioid crisis. The decision was announced on Tuesday, allowing more public engagement in the legal proceedings as the pharmaceutical giant faces scrutiny over its opioid marketing.
The anticipated court hearing in Newark, New Jersey, was to finalize Purdue Pharma's 2020 guilty plea in a case that could levy a $3.5 billion criminal fine, plus $2 billion in criminal forfeiture against Purdue. The company's actions have been linked to an opioid epidemic that has tragically claimed over a million lives in the United States since the turn of the millennium.
In related pharmaceutical industry news, Johnson & Johnson has announced plans to offer four prescription medications on the Trump administration's TrumpRx website. This expansion involves diabetes medications Invokamet, Invokamet XR, and Invokana, along with the blood thinner Xarelto, marking a significant step in the company's direct-to-consumer strategy.
(With inputs from agencies.)
Google News